Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients

Michela Mantelli, Lorenza Pastorino, Paola Ghiorzo, Monica Barile, William Bruno, Sara Gargiulo, Maria Pia Sormani, Sara Gliori, Stefania Vecchio, Paola Ciotti, Mario Roberto Sertoli, Paola Queirolo, Alisa M. Goldstein, Giovanna Bianchi-Scarrà

Research output: Contribution to journalArticlepeer-review


Although the presence of multiple cases of melanoma on the same side of a family is the best predictor of germline CDKN2A mutation, other features (i.e. early age at onset) may be useful to identify carriers. We analysed the records of 682 hospital-based Ligurian melanoma patients. Of these, 238 cases (34 familial, 14 non-familial multiple primary and 190 non-familial single primary melanomas) were consecutively enrolled for screening of the CDKN2A and CDK4 genes. Screening of the 34 familial patients revealed that nine were carriers of the CDKN2A G101W founder mutation. Of the 14 non-familial multiple primary melanoma patients, three carried the G101W founder mutation and one the P48T mutation. For the non-familial patients with a single melanoma, 17 of 190 carried germline CDKN2A mutations, with most (16/17) carrying the G101W Ligurian founder mutation and one a novel single base pair substitution, D74Y. The effect of mutation on age at diagnosis was significant (P=0.012) after correcting for melanoma type (familial or non-familial), number of primaries (single or multiple), gender and disease occurrence (incident or prevalent). Early age at onset may be a good predictor of CDKN2A mutation in Liguria, where the G101W founder mutation is prevalent among melanoma patients, independent of family history.

Original languageEnglish
Pages (from-to)443-448
Number of pages6
JournalMelanoma Research
Issue number6
Publication statusPublished - Dec 2004


  • CDKN2A
  • Early age at onset
  • G101W founder mutation
  • Liguria
  • Melanoma patients

ASJC Scopus subject areas

  • Cancer Research
  • Dermatology


Dive into the research topics of 'Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients'. Together they form a unique fingerprint.

Cite this